Evolving strategies in the management of submacular hemorrhage associated with choroidal neovascularization in the anti-vascular endothelial growth factor era

Retina

Volumn 31, Issue 9, 2011, Pages 1749-1752

  Todorich, Bozho ^a   Scott, Ingrid U ^a   Flynn, Harry W ^b   Johnson, Mark W ^c  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN ANTIBODY;

DISEASE ASSOCIATION; DRUG EFFICACY; EYE SURGERY; HUMAN; MONOTHERAPY; NONHUMAN; PIGMENT EPITHELIUM; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; RETINA MACULA HEMORRHAGE; REVIEW; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

ANTIBODIES, MONOCLONAL; CHOROID HEMORRHAGE; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; MACULAR DEGENERATION; MALE;

EID: 80053369289     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31821504df     Document Type: Review

References (40)

1. Chang MA, Do DV, Bressler SB, Cassard SD, Gower EW, Bressler NM. Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. Retina 2010;30:1171-1176.
2. Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol 1982;94:762-773.
3. Toth CA, Morse LS, Hjelmeland LM, Landers MB 3rd. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol 1991;109:723-729.
4. Bennett SR, Folk JC, Blodi CF, Klugman M. Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol 1990;109:33-37.
5. Avery RL, Fekrat S, Hawkins BS, Bressler NM. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina 1996;16:183-189.
6. Berrocal MH, Lewis ML, Flynn HW Jr. Variations in the clinical course of submacular hemorrhage [published erratum appears in Am J Ophthalmol 1996;122:920].
7. Am J Ophthalmol 1996;122:486-493.
8. Mandelcorn MS, Menezes AV. Surgical removal of subretinal hemorrhage and choroidal neovascular membranes in acute hemorrhagic age-related macular degeneration. Can J Ophthalmol 1993;28:19-23.
9. Dellaporta A. Endodiathermy for retinal detachment with macular hole. Am J Ophthalmol 1983;95:405-407.
10. Rubsamen PE, Flynn HW Jr., Civantos JM, et al. Treatment of massive subretinal hemorrhage from complications of scleral buckling procedures. Am J Ophthalmol 1994;118:299-303.
11. Ibanez HE, Williams DF, Thomas MA, et al. Surgical management of submacular hemorrhage. A series of 47 consecutive cases. Arch Ophthalmol 1995;113:62-69.
12. Wade EC, Flynn HW Jr., Olsen KR, Blumenkranz MS, Nicholson DH. Subretinal hemorrhage management by pars plana vitrectomy and internal drainage. Arch Ophthalmol 1990;108:973-978.
13. Brent BD, Gonce M, Diamond JG. Pars plana vitrectomy for complications of retinal arterial macroaneurysms-a case series. Ophthalmic Surg 1993;24:534-536.
14. Johnson MW, Olsen KR, Hernandez E. Tissue plasminogen activator thrombolysis during surgical evacuation of experimental subretinal hemorrhage. Ophthalmology 1992;99: 515-521.
15. Benner JD, Hay A, Landers MB 3rd, Hjelmeland LM, Morse LS. Fibrinolytic-assisted removal of experimental subretinal hemorrhage within seven days reduces outer retinal degeneration. Ophthalmology 1994;101:672-681.
16. Coll GE, Sparrow JR, Marinovic A, Chang S. Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage. Retina 1995;15:319-326.
17. Lewis H. Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage. Am J Ophthalmol 1994;118:559-568.
18. Lim JI, Drews-Botsch C, Sternberg P Jr., Capone A Jr., Aaberg TM Sr. Submacular hemorrhage removal. Ophthalmology 1995;102:1393-1399.
19. Childs AL, Bressler NM, Bass EB, et al; Submacular Surgery Trials (SST) Research Group. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Quality-of-life findings: SST report no. 14. Ophthalmology 2004;111:2007-2014.
20. Machemer R, Steinhorst UH. Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration? Graefes Arch Clin Exp Ophthalmol 1993;231:635-641.
21. Wong D, Stanga P, Briggs M, et al. Case selection in macular relocation surgery for age related macular degeneration. Br J Ophthalmol 2004;88:186-190.
22. Gibran SK, Romano MR, Wong D. Perfluorocarbon liquid assisted large retinal epithelium patching in sub-macular hemorrhage secondary to age related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009;247:187-191.
23. Ma Z, Han L, Wang C, et al. Autologous transplantation of retinal pigment epithelium-Bruch's membrane complex for hemorrhagic age-related macular degeneration. Invest Ophthalmol Vis Sci 2009;50:2975-2981.
24. MacLaren RE, Uppal GS, Balaggan KS, et al. Autologous transplantation of the retinal pigment epithelium and choroid in the treatment of neovascular age-related macular degeneration. Ophthalmology 2007;114:561-570.
25. Ahmad S, Bearelly S, Stinnett SS, Cooney MJ, Fekrat S. Photodynamic therapy for predominantly hemorrhagic lesions in neovascular age-related macular degeneration. Am J Ophthalmol 2008;145:1052-1057.
26. Hassan AS, Johnson MW, Schneiderman TE, et al. Management of submacular hemorrhage with intravitreous tPA injection and pneumatic displacement. Ophthalmology 1999; 106:1900-1906.
27. Gopalakrishan M, Giridhar A, Bhat S, Saikumar SJ, Elias A, NS. Pneumatic displacement of submacular hemorrhage: Safety, efficacy, and patient selection. Retina 2007;27:329-334.
28. Fang IM, Lin YC, Yang CH, Yang CM, Chen MS. Effects of intravitreal gas with or without tissue plasminogen activator on submacular haemorrhage in age-related macular degeneration. Eye (Lond) 2009;23:397-406.
29. Johnson MW. Pneumatic displacement of submacular hemorrhage. Curr Opin Ophthalmol 2000;11:201-206.
30. Haupert CL, McCuen BW 2nd, Jaffe GJ, et al. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol 2001;131:208-215.
31. Olivier S, Chow DR, Packo KH, MacCumber MW, Awh CC. Subretinal recombinant tissue plasminogen activator injection and pneumatic displacement of thick submacular hemorrhage in age-related macular degeneration [published erratum appears in Ophthalmology 2004;111:1640].
32. Ophthalmology 2004;111:1201-1208.
33. Singh RP, Patel C, Sears JE. Management of subretinal macular haemorrhage by direct administration of tissue plasminogen activator. Br J Ophthalmol 2006;90:429-431.
34. Höhn F, Mirshahi A, Hattenbach LO. Combined intravitreal injection of bevacizumab and SF6 gas for treatment of submacular hemorrhage secondary to age-related macular degeneration. Ophthalmologe 2010;107:328-332.
35. Matt G, Sacu S, Stifter E, Prünte C, Schmidt-Erfurth U. Combination of intravitreal rTPA, gas and ranibizumab for extensive subfoveal haemorrhages secondary to neovascular age-related macular degeneration [in German]. Klin Monbl Augenheilkd 2010;227:221-225.
36. Ferraz DA, Bressanim GL, Morita C, Takahashi WY. Intravitreous injection of bevacizumab and C3F8 gas for the treatment of submacular hemorrhage due to age-related macular degeneration: Case reports. Arq Bras Oftalmol 2010; 73:77-80.
37. Meyer CH, Scholl HP, Eter N, Helb HM, Holz FG.Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: A retrospective pilot study. Acta Ophthalmol 2008;86:490-494.
38. Stifter E, Michels S, Prager F, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am J Ophthalmol 2007;144: 886-892.
39. Olmos L, Flynn HW Jr., Leung E. Submacular hemorrhage associated with age-related macular degeneration: Favorable response to treatment with intravitreal ranibizumab alone. Ophthalmology Management AMD Update (Internet). 2010 Oct;46 http://www.visioncareprofessional.com/emails/amdupdate/ index.asp?issue=46.
40. Thompson JT, Sjaarda RN. Vitrectomy for the treatment of submacular hemorrhages from macular degeneration: A comparison of submacular hemorrhage/membrane removal and submacular tissue plasminogen activator-assisted pneumatic displacement. Trans Am Ophthalmol Soc 2005;103:98-107.